Piper Jaffray Reiterates Outperform Following Catalent's (CTLT) 2Q Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Catalent, Inc. Reports Second Quarter 2016 Results
February 9, 2016 4:16 PM ESTRevenue in line with prior year as reported and increased 6% in constant currency to $454.9 million from second quarter 2015 Adjusted Net Income totaled $44.9 million, or $0.36 per diluted share Entered into a research collaboration with Roche to develop next generation molecules using Catalents proprietary SMARTag technology Announced a long-term exclusive agreement with Pfizer to produce Nexium® 24HR, its leading OTC heartburn medication
SOMERSET, N.J.--(BUSINESS WIRE)-- Catalent, Inc. (NYSE:... More
